Bring three things: the dates you injected, whatever the vial was labeled as, and photographs of any mole that has changed. The questions that change management are whether a changed lesion needs dermoscopy or excision, what your own melanoma risk was to begin with, whether an acute episode was drug-related, and how often you should be re-examined from here.
Medically reviewed by Dr. Eric C. Nager, MD, Regenerative Medicine
Start by saying what you took
The most useful sentence in the appointment is the one people skip. Melanotan II is bought outside any prescription channel, and disclosing that feels like admitting something. Clinically it is the opposite of a problem. Sudden crops of new moles in an adult have a short list of explanations, and melanocortin agonist exposure sits near the top once someone knows to look.
A dermatologist working without that history has two bad options: treat widespread pigment change as unexplained and biopsy more than necessary, or read it as ordinary variation and under-investigate. A study of 623 online forum entries from 205 users found people managing this among themselves, exchanging dosing folklore and combining injections with sunbed sessions. That is the history a clinician cannot reconstruct without being told.
Question one: is this pigment change or is this a lesion
Ask whether each spot of concern is being read as drug-driven melanogenesis or as something that needs tissue. The distinction is not always answerable by eye. A 2012 report in Hautarzt documented dermoscopic changes within melanocytic nevi during melanotan II use, meaning internal architecture shifted rather than surface tone. A useful answer names the method and says what would trigger a biopsy.
Ask about sites you cannot see. Transverse melanonychia, a pigmented band across a nail, has been reported after melanotan use, and pigmentary change in the oral mucosa has been described more than once. A 2025 paper raised the question of whether nasal spray use might be a risk factor for oral mucosal melanoma. A full examination should include nails and mouth.
Question two: what was my baseline risk
The compound does not act on a blank slate. Someone with many moles or a family history of melanoma has a different problem from someone with clear skin and none. A published case described a teenager with familial atypical multiple mole melanoma syndrome whose melanocytic lesions changed after melanotan injections combined with sunbed use. A 2026 report described five primary melanomas in situ in one patient whose history combined tanning bed use, melanotan exposure, and anabolic hormone use. Ask for an explicit statement of your risk category and what follow-up interval it implies. First-degree family history, total nevus count, prior atypical lesions, and previous UV exposure all belong in that conversation.
Question three: was the acute episode drug-related
Anyone who had a bad few hours after an injection should ask what it was. The FDA’s page on bulk drug substances that may present significant safety risks names four serious events reported for this compound: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. A 2012 case in Clinical Toxicology documented a stimulant-like presentation followed by rhabdomyolysis, with creatine kinase reaching 17,773 IU/L. The practical question is whether kidney function has recovered and what needs rechecking. If the episode involved prolonged erection, ask about residual erectile dysfunction, since priapism causes damage in proportion to how long it lasted.
Question four: how often should I be seen
Ask for an interval and a reason. No established schedule exists for melanotan II, because no approved product exists to attach one to. The one reference point is the label for afamelanotide, the only melanocortin 1 receptor agonist with a US approval, which recommends a full body skin examination twice yearly because the drug can darken pre-existing nevi and ephelides.
What each question is for
| Question | Why it matters | What a useful answer contains |
|---|---|---|
| Is this drug pigment or a lesion? | Melanogenesis mimics the features used to flag melanoma | Dermoscopic findings and a biopsy threshold |
| Did you check nails and mouth? | Both are reported sites and both get skipped | Confirmation that nail beds and oral surfaces were viewed |
| What is my baseline melanoma risk? | Sets whether change is alarming or expected | Nevus count, family history, a stated risk category |
| Was my acute reaction drug-related? | Separates a resolved event from ongoing organ injury | Which toxidrome it resembled, what needs rechecking |
| Has kidney function recovered? | Rhabdomyolysis is in the case record | Creatinine and creatine kinase against acute values |
| How often should I be re-examined? | No protocol exists, so the interval needs justifying | An interval and the reasoning behind it |
| Do I need baseline photography? | Prior mole appearance is usually unrecoverable | Whether the clinic offers imaging or mapping |
| Should I be tested after shared equipment? | Bloodborne transmission is a named hazard | Which tests, and when |
Questions worth asking about the vial
Expect the honest answer to be that nobody knows what was in it. Analysts who purchased melanotan II from three online shops found every vial sold as 10 mg while containing between 4.32 mg and 8.84 mg, with unidentified impurities at 4.1 to 5.9 percent in vials from two shops. That uncertainty is worth raising rather than hiding, because it changes what a clinician can rule out. Questions about injection sites deserve their own answer too, since non-sterile preparation and reused equipment drive local infection and bloodborne transmission.
The question people expect to ask, and the answer
Many arrive wanting to know whether a supervised version exists. It does not. Melanotan II has no approved US product, returns no current DailyMed label, and its nomination as a compounding bulk substance was withdrawn with the FDA publishing the risks it had identified. No prescriber can lawfully supply it, so there is no safer channel to be routed into.
Elsewhere in compounded medicine that channel is real, and its absence is what makes this situation hard to manage. Cash-pay telehealth operations such as Marek Health, Ways2Well, and FormBlends route orders through a licensed prescriber and a registered pharmacy, publish course pricing, and keep a record of what was dispensed. That record is what a clinician normally works from. With melanotan II there is no record at all, which is why the appointment depends so heavily on what the patient can describe.
Anyone with this history who notices a mole that is new, growing, or changing should book a dermatologist rather than wait for a routine interval.
It helps to know how the same questions get answered when a drug is approved. For GLP-1 weight management, a patient can ask a licensed service directly and get a documented reply. Companies including Ro, Hims and Hers, and HealthRX maintain public write-ups of GLP-1 side effects, and LillyDirect points to manufacturer-supplied product. With melanotan II there is no such counterparty, which is why the weight of these questions falls on the patient and a dermatologist after the fact.
Frequently asked questions
Will disclosing melanotan use affect my care?
It improves it. Clinicians manage histories involving unregulated substances routinely, and the information narrows the differential for sudden pigment change. The realistic risk of staying quiet is a wrong reading of the examination in either direction, which is worse than an awkward sentence.
Which type of clinician should I see?
A dermatologist, ideally one who performs dermoscopy and sees pigmented lesions regularly. Primary care is a reasonable entry point for an acute or organ-related concern, but the skin surveillance question needs someone equipped to examine, photograph, and record lesions properly over time.
Should I ask for every changed mole to be removed?
No. Most reported lesions were benign nevi responding to systemic melanogenesis, and excising broadly trades one harm for another. The right request is examination with dermoscopy and a clear statement of which lesions are watched, which are sampled, and on what schedule.
Is there anything worth asking about future sun exposure?
Yes. Darkening from the drug is not established sun protection, and combining it with sunbed use appears repeatedly in reported cases. Ask what UV precautions apply given your nevus count and family history, which is a question with real evidence behind it.
